Study of a new immunotherapy for advanced solid tumors
Part of Cancer clinical trials.
This study is testing a new two-in-one immunotherapy drug (QL1706) for people with advanced cancers like lung, breast, colon, or liver cancer that have gotten worse after at least one prior treatment. It aims to see how well the drug works in real-world settings.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of advanced cancer (like lung, breast, colon, or liver cancer) that has continued to grow after at least one standard treatment.
- You are able to take care of yourself (up to needing some help for daily activities).
- You have at least one tumor that can be measured on scans.
- Your blood counts, liver and kidney function, and other lab results are within study ranges (like enough white blood cells and healthy liver function).
- You have not had treatment with certain other immunotherapy drugs (those targeting CTLA-4 or other checkpoints).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs (QLC5513 and QL1706) for people with advanced or metastatic solid tumors that cannot be removed by surgery or radiation. The goal is to see if this combination is safe and effective.
This Phase 1 trial tests a new drug called IUAb190708 designed to help your immune system fight advanced or recurrent solid cancers. The study will evaluate its safety, how your body handles it, and whether it works against your tumor.
This trial tests a new drug called QLS5212 in people with solid tumors that have spread or cannot be removed by surgery. The goal is to see if the drug is safe and effective.
This trial tests if adding a new immunotherapy drug (QL1706) to standard chemotherapy works better than chemotherapy alone for triple-negative breast cancer that has returned or spread. This is for people who have already tried 1 or 2 other treatments.
This trial tests a new drug called QL1706 combined with chemotherapy for people with non-small cell lung cancer that has spread or come back after previous treatment with an immunotherapy drug (PD-1/PD-L1 inhibitor) plus chemotherapy. The goal is to see if this combination can help shrink or control the cancer.
This trial tests a combination of two new treatments (QLP2117 and QL2107) for people with advanced solid tumors that have not responded to standard therapy. The goal is to see if the combination can shrink tumors or slow cancer growth.
Hear when a new Solid Tumor Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.